Healthy Skepticism Library item: 4855
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
 
Publication type: Journal Article
Lichtenberg FR.
Pharmaceutical innovation and the burden of disease in developing and developed countries.
J Med Philos 2005 Dec; 30:(6):663-90
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16396790&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=0360-5310&volume=30&issue=6&spage=663
Abstract:
I perform two analyses of the relationship across diseases between pharmaceutical innovation and the burden of disease in developed and developing countries. Both analyses indicate that the amount of pharmaceutical innovation is positively related to the burden of disease in developed countries but not to the burden of disease in developing countries. The most plausible explanation for the lack of a relationship between the burden of disease in developing countries and the amount of pharmaceutical innovation is that incentives for firms to develop medicines for diseases primarily afflicting people in developing countries have been weak or nonexistent.
Keywords:
Developed Countries/statistics & numerical data*
Developing Countries/statistics & numerical data*
Drug Industry*
Humans
Morbidity*
Mortality
World Health Organization